Fiona Xu
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Histone Deacetylase Inhibitors Research, Ubiquitin and proteasome pathways, Renal cell carcinoma treatment
Most-Cited Works
- → High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response(2015)1,424 cited
- → NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma(2013)73 cited
- → Cabozantinib in combination with atezolizumab in non-clear cell renal cell carcinoma: Extended follow-up results of cohort 10 of the COSMIC-021 study.(2023)5 cited
- → Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002(2023)2 cited
- → STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.(2024)1 cited
- → Abstract PS7-02: First-in-human results of STX-478, a mutant-selective PI3K alpha inhibitor, in HR+ breast cancer and advanced solid tumor patients(2025)1 cited
- → Supplementary Table 3 from NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma(2023)
- → High-throughput, single-cell drug response measurement using quantitative phase microscopy(2023)
- → Supplementary Figure from NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma(2023)
- → Abstract 2612: ljm716, an anti her3 antibody that inhibits her3 dimerization, displays anti-tumor activity in esophageal squamous cell cancer(2014)